Roche breast cancer drug Itovebi turned down by NICE
NICE turns down NHS use of Roche's breast cancer drug Itovebi, which the company says reveals a flaw in the appraisal of combination therapies.
Newsletters and Deep Dive digital magazine
NICE turns down NHS use of Roche's breast cancer drug Itovebi, which the company says reveals a flaw in the appraisal of combination therapies.
Patients should be involved in the programme design process from the beginning, as co-creators with full influence over the outcome.
Women and girls with autoimmune diseases are more likely to have their condition misdiagnosed as psychiatric or psychosomatic than males, study finds.
A study has shown that the efficacy of Lilly's psoriasis therapy Taltz is improved when it is given in combination with weight-loss drug Zepbound.
For many Hispanic patients and families, that is where the gap between need and treatment can begin.
Editor's Picks
Newsletters and Deep Dive
digital magazine
Editor's Picks